DOCSLIB.ORG

A Guide to Cancer Immunotherapy: from T Cell Basic Science to Clinical Practice

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Guide to Cancer Immunotherapy: from T Cell Basic Science to Clinical Practice REVIEWS A guide to cancer immunotherapy: from T cell basic science to clinical practice Alex D. Waldman 1,2, Jill M. Fritz1,2 and Michael J. Lenardo 1,2 ✉ Abstract | The T lymphocyte, especially its capacity for antigen-directed cytotoxicity, has become a central focus for engaging the immune system in the fight against cancer. Basic science discoveries elucidating the molecular and cellular biology of the T cell have led to new strategies in this fight, including checkpoint blockade, adoptive cellular therapy and cancer vaccinology. This area of immunological research has been highly active for the past 50 years and is now enjoying unprecedented bench-to-bedside clinical success. Here, we provide a comprehensive historical and biological perspective regarding the advent and clinical implementation of cancer immunotherapeutics, with an emphasis on the fundamental importance of T lymphocyte regulation. We highlight clinical trials that demonstrate therapeutic efficacy and toxicities associated with each class of drug. Finally, we summarize emerging therapies and emphasize the yet to be elucidated questions and future promise within the field of cancer immunotherapy. Neoantigens The idea to deploy the immune system as a tool to treat system to prevent carcinogenesis in a manner similar to 1 1 Antigens not expressed by neoplastic disease originated in the nineteenth century . graft rejection . Productive immune responses following self-tissues under normal Wilhelm Busch and Friedrich Fehleisen were the first tumoural adoptive transfer in mice4 and clinical reports conditions that manifest in to describe an epidemiological association between of spontaneous regression of melanoma in patients with the context of pathology; in 5 cancer, these could be altered immune status and cancer. They noticed spontaneous concomitant autoimmune disease provided additional proteins/peptides encoded by regression of tumours following the development of evidence supporting this hypothesis, although a unifying mutated genes. erysipelas, a superficial skin infection most commonly mechanism was elusive. The advent of knockout mouse caused by Streptococcus pyogenes1. Later, William Coley, models provided the necessary technology to experi­ Immune checkpoint often called the ‘Father of Cancer Immunotherapy’, retro­ mentally demonstrate a link between immunodeficiency A mechanism of immune 6 cell inhibition that restrains spectively demonstrated that erysipelas was associated and cancer . Additional molecular and biochemical 2 activation. with a better outcome in patients with sarcoma . With advances led to the identification of tumour­specific hopes of prospectively verifying his epidemiological evi­ immune responses7. This provided unequivocal evi­ dence, Coley treated patients with cancer with extracts dence that the immune system, in particular T cells (see of heat­inactivated S. pyogenes and Serratia marcescens BOx 1 and Fig. 1), was capable of waging war on cancer 3 7 1Molecular Development of to boost immunity . This extract, termed ‘Coley’s tox­ tissue . Cancer immunotherapy has now revolutionized the Immune System Section, ins’, possessed potent immunostimulatory properties the field of oncology by prolonging survival of patients Laboratory of Immune and achieved favourable responses in various cancers2. with rapidly fatal cancers. The number of patients eligi­ System Biology, National However, lack of scientific rigour and reproducibility, in ble for immune­based cancer treatments continues to Institute of Allergy and concert with the discovery of radiotherapy and chemo­ skyrocket as these therapies position themselves as the Infectious Diseases, National Institutes of Health, therapeutic agents, prevented treatment with ‘Coley’s first line for many cancer indications. Novel treatment 1 Bethesda, MD, USA. toxins’ from becoming standard practice . combinations and newly identified druggable targets will 2Clinical Genomics Program, The concept of cancer immunotherapy resurfaced only expand the role of immunotherapy in the treatment Division of Intramural in the twentieth century and made significant headway of cancer in the decades to come. Research, National Institute with the advent of new technology. In 1909, Paul Ehrlich In this Review, we emphasize the role of T cells in of Allergy and Infectious hypothesized that the human body constantly gen erates modern cancer immunotherapies and discuss three dif­ Diseases, National Institutes of Health, Bethesda, neoplastic cells that are eradicated by the immune ferent categories of immunotherapeutic approaches to 3 MD, USA. sys tem . Lewis Thomas and Sir Frank Macfarlane treat cancer: immune checkpoint blockade, an approach ✉e-mail: [email protected] Burnet independently conceived the ‘cancer immuno­ that is designed to ‘unleash’ powerful T cell responses; https://doi.org/10.1038/ surveillance’ hypothesis, stating that tumour­associated adoptive cellular therapies, which are based on the infu­ s41577-020-0306-5 neoantigens are recognized and targeted by the immune sion of tumour­fighting immune cells into the body; and NATURE REVIEWS | IMMUNOLOGY VOLUME 20 | NOVEMBER 2020 | 651 REVIEWS Box 1 | T cell function, development, activation and fate The 1960s represented a period of enlightenment within the field of provided by studies demonstrating the efficient inhibition of T cell immunology because two major subtypes of lymphocytes, B lymphocytes acti vation and proliferation by inhibitory anti­CD28 antibodies275–278. and T lymphocytes, were characterized264,265. This was recognized by the The ligands for CD28, B7­1 and B7­2, are expressed on antigen­presenting 2019 Lasker Award for Basic Science, awarded for the pioneering work cells and are upregulated when these cells encounter microorganisms by Jacques A. F. P. Miller and Max Dale Cooper that defined the key roles that activate Toll­like receptors or other pathogen sensors279,280. Inhibitory of T cells and B cells in adaptive immunity. B cells recognize circulating molecules, including cytotoxic T lymphocyte­associated protein 4 antigen in its native form and respond by secreting protective anti­ (CTLA4) and programmed cell death 1 (PD1), are induced during immune bodies266. By contrast, T cells recognize peptide antigens, derived from responses and represent a ‘checkpoint’ to dampen T cell hyperactivation281 proteins degraded intracellularly, that are loaded onto cell surface MHC (see Fig. 2). The polymorphic TCR signals through a complex of three molecules, a process called antigen presentation. Two broad classes sets of dimeric CD3 chains, ε–δ, γ–δ and ζ– ζ282. The intracellular portions of T cells that have distinct effector mechanisms are delineated by the of the CD3 chains contain immunoreceptor tyrosine­based activation expression of either the CD4 or CD8 co­receptor: CD4+ T cells detect motifs that are phosphorylated by lymphocyte­specific protein kinase antigen in the context of MHC class II molecules and orchestrate the (LCK), a SRC family kinase283. At rest, the surface signalling protein CD45 adaptive arm of the immune system by producing cytokines with exhibits phosphatase activity that blocks LCK function284. Following chemo tactic, pro­inflammatory and immunoprotective properties267. activation, CD45 removes an inhibitory phosphate on LCK, permitting At least one CD4+ T cell subclass, CD4+CD25+ regulatory T cells, dampens phosphorylation of ζ chain­associated protein kinase 70 (ZAP70), a SYK the immune response following challenge268. CD8+ T cells detect antigen kinase family member that binds to immunoreceptor tyrosine­based in the context of MHC class I molecules and carry out direct cytotoxic activation motifs in the CD3 ζ­chain and recruits the linker for activation of reactions that kill infected or neoplastic cells269. T cells (LAT) and phospholipase Cγ1 (PLCγ)285. With ample co­stimulation, A unique clone­specific cell surface protein complex, the T cell downstream signalling affects calcium release, the activation of the receptor (TCR), specifically recognizes antigens and participates in the GTPase RAS and transcriptional reprogramming essential for activated developmental selection of T cells that can recognize pathogens but are T cell function286. self­tolerant270. The TCR complex comprises highly polymorphic single Following activation, circulating naive T cells have three major α­ and β­glycoprotein chains (a small T cell population harbours γ­ and fates in the periphery (Fig. 1). First, the effector T cell population δ­chains instead) that contain variable and constant regions, akin to can contract through apoptosis as the immune response resolves immunoglobulins, and a group of non­polymorphic signalling chains, (cytokine withdrawal) or following repeated high­dose stimulation called CD3 γ, δ, ε and ζ. A vast repertoire of T cell clonotypes with unique (restimulation­induced cell death)287–289. T cells can also exhibit an specificities is generated through rearrangement of α­ and β­chain exhausted phenotype induced by repeated low­dose and low­affinity gene segments within the genome of each T cell271. Following clonotype stimulation, as seen in chronic infections and neoplastic processes88. production, positive and negative thymic selection functions to entrain Lastly, a subset of these effector cells are involved in long­term a ‘tolerant’ immune system, one that efficiently responds to pathogens immunological memory. Memory T cells are primed to react more or cancer cells but generally ignores or ‘tolerates’ self­tissues
Load more

Recommended publications
  • Human Nerual Stem Cells for Brain Repair
    International Journal of Stem Cells Vol. 1, No. 1, 2008 REVIEW ARTICLE Human Nerual Stem Cells for Brain Repair Seung U. Kim1,2, Hong J. Lee1, In H. Park1, Kon Chu3, Soon T. Lee3, Manho Kim3, Jae K. Roh3, Seung K. Kim4, Kyu C. Wang4 1Institute for Regenerative Medicine, Gachon Medical University Gil Hospital, Incheon, Korea, 2Division of Neurology, Department of Medicine, UBC Hospital, University of British Columbia, Vancouver, Canada, Departments of 3Neurology and 4Neurosurgery, Seoul National University Hospital, Seoul, Korea Cell replacement therapy and gene transfer to the diseased or injured brain have provided the basis for the development of potentially powerful new therapeutic strategies for a broad spectrum of human neurological diseases including Parkinson disease, Huntington disease, amyotrophic lateral sclerosis (ALS), Alzheimer disease, multiple sclerosis (MS), stroke, spinal cord injury and brain cancer. In recent years, neurons and glial cells have successfully been generated from neural stem cells, and extensive efforts by investigators to develop neural stem cell-based transplantation therapies have been carried out. We review here notable experimental and pre-clinical studies we have previously conducted involving human neural stem cell-based cell- and gene-therapies for Parkinson disease, Huntington disease, ALS, stroke and brain cancer. Keywords: Stem cell, Human neural stem cell, Cell therapy, Gene transfer, Transplantation, Neurodegenrative diseases, Parkinson disease, Huntington disease, Amyotrophic lateral sclerosis, Stroke, Brain cancer neural stem cells (NSCs) could be isolated from various Introduction tissues. Existence of multipotent NSCs has been known in developing or adult rodent or human brain with proper- Stem cells are the cells that have the ability to renew ties of indefinite growth and multipotent potential to dif- themselves continuously and possess pluripotent ability to ferentiate into three major cell types of CNS, neurons, as- differentiate into many cell types.
    [Show full text]
  • Effects of Chemotherapy Agents on Circulating Leukocyte Populations: Potential Implications for the Success of CAR-T Cell Therapies
    cancers Review Effects of Chemotherapy Agents on Circulating Leukocyte Populations: Potential Implications for the Success of CAR-T Cell Therapies Nga T. H. Truong 1, Tessa Gargett 1,2,3, Michael P. Brown 1,2,3,† and Lisa M. Ebert 1,2,3,*,† 1 Translational Oncology Laboratory, Centre for Cancer Biology, University of South Australia and SA Pathology, North Terrace, Adelaide, SA 5000, Australia; [email protected] (N.T.H.T.); [email protected] (T.G.); [email protected] (M.P.B.) 2 Cancer Clinical Trials Unit, Royal Adelaide Hospital, Port Rd, Adelaide, SA 5000, Australia 3 Adelaide Medical School, University of Adelaide, North Terrace, Adelaide, SA 5000, Australia * Correspondence: [email protected] † These authors contributed equally. Simple Summary: CAR-T cell therapy is a new approach to cancer treatment that is based on manipulating a patient’s own T cells such that they become able to seek and destroy cancer cells in a highly specific manner. This approach is showing remarkable efficacy in treating some types of blood cancers but so far has been much less effective against solid cancers. Here, we review the diverse effects of chemotherapy agents on circulating leukocyte populations and find that, despite some negative effects over the short term, chemotherapy can favourably modulate the immune systems of cancer patients over the longer term. Since blood is the starting material for CAR-T cell Citation: Truong, N.T.H.; Gargett, T.; production, we propose that these effects could significantly influence the success of manufacturing, Brown, M.P.; Ebert, L.M.
    [Show full text]
  • Applications of Mesenchymal Stem Cells in Skin Regeneration and Rejuvenation
    International Journal of Molecular Sciences Review Applications of Mesenchymal Stem Cells in Skin Regeneration and Rejuvenation Hantae Jo 1,† , Sofia Brito 1,†, Byeong Mun Kwak 2,3,† , Sangkyu Park 4,* , Mi-Gi Lee 5,* and Bum-Ho Bin 1,4,* 1 Department of Applied Biotechnology, Ajou University, Suwon 16499, Korea; [email protected] (H.J.); sofi[email protected] (S.B.) 2 Department of Meridian and Acupoint, College of Korean Medicine, Semyung University, Chungbuk 27136, Korea; [email protected] 3 School of Cosmetic Science and Beauty Biotechnology, Semyung University, 65 Semyung-ro, Jecheon-si, Chungcheongbuk-do 27136, Korea 4 Department of Biological Sciences, Ajou University, Suwon 16499, Korea 5 Bio-Center, Gyeonggido Business and Science Accelerator, Suwon 16229, Korea * Correspondence: [email protected] (S.P.); [email protected] (M.-G.L.); [email protected] (B.-H.B.); Tel.: +82-31-219-2967 (S.P.); +82-31-888-6952 (M.-G.L.); +82-031-219-2816 (B.-H.B.) † These authors contributed equally to this study. Abstract: Mesenchymal stem cells (MSCs) are multipotent stem cells derived from adult stem cells. Primary MSCs can be obtained from diverse sources, including bone marrow, adipose tissue, and umbilical cord blood. Recently, MSCs have been recognized as therapeutic agents for skin regeneration and rejuvenation. The skin can be damaged by wounds, caused by cutting or breaking of the tissue, and burns. Moreover, skin aging is a process that occurs naturally but can be worsened by environmental pollution, exposure to ultraviolet radiation, alcohol consumption, tobacco use, and undernourishment. MSCs have healing capacities that can be applied in damaged and aged Citation: Jo, H.; Brito, S.; Kwak, B.M.; Park, S.; Lee, M.-G.; Bin, B.-H.
    [Show full text]
  • Naeglaria and Brain Infections
    Can bacteria shrink tumors? Cancer Therapy: The Microbial Approach n this age of advanced injected live Streptococcus medical science and into cancer patients but after I technology, we still the recipients unfortunately continue to hunt for died from subsequent innovative cancer therapies infections, Coley decided to that prove effective and safe. use heat killed bacteria. He Treatments that successfully made a mixture of two heat- eradicate tumors while at the killed bacterial species, By Alan Barajas same time cause as little Streptococcus pyogenes and damage as possible to normal Serratia marcescens. This Alani Barajas is a Research and tissue are the ultimate goal, concoction was termed Development Technician at Hardy but are also not easy to find. “Coley’s toxins.” Bacteria Diagnostics. She earned her bachelor's degree in Microbiology at were either injected into Cal Poly, San Luis Obispo. The use of microorganisms in tumors or into the cancer therapy is not a new bloodstream. During her studies at Cal Poly, much idea but it is currently a of her time was spent as part of the undergraduate research team for the buzzing topic in cancer Cal Poly Dairy Products Technology therapy research. Center studying spore-forming bacteria in dairy products. In the late 1800s, German Currently she is working on new physicians W. Busch and F. chromogenic media formulations for Fehleisen both individually Hardy Diagnostics, both in the observed that certain cancers prepared and powdered forms. began to regress when patients acquired accidental erysipelas (cellulitis) caused by Streptococcus pyogenes. William Coley was the first to use New York surgeon William bacterial injections to treat cancer www.HardyDiagnostics.com patients.
    [Show full text]
  • And High-Dose Cyclophosphamide
    141-146 6/6/06 13:01 Page 141 ONCOLOGY REPORTS 16: 141-146, 2006 141 Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide YASUHIDE MOTOYOSHI1,2, KAZUHISA KAMINODA1,3, OHKI SAITOH1, KEISUKE HAMASAKI2, KAZUHIKO NAKAO3, NOBUKO ISHII3, YUJI NAGAYAMA1 and KATSUMI EGUCHI2 Departments of 1Medical Gene Technology, Atomic Bomb Disease Institute; 2Division of Immunology, Endocrinology and Metabolism, Department of Medical and Dental Sciences, and 3Division of Clinical Pharmaceutics and Health Research Center, Nagasaki University Graduate School of Biomedical Sciences, 1-12-4 Sakamoto, Nagasaki 852-8501, Japan Received February 3, 2006; Accepted April 7, 2006 Abstract. It is known that, besides its direct cytotoxic effect appear to be highly crucial in a clinical setting of combined as an alkylating chemotherapeutic agent, cyclophosphamide chemotherapy and immunotherapy for cancer treatment. also has immuno-modulatory effects, such as depletion of CD4+CD25+ regulatory T cells. However, its optimal concen- Introduction tration has not yet been fully elucidated. Therefore, we first compared the effects of different doses of cyclophosphamide Chemotherapy and immunotherapy are generally regarded on T cell subsets including CD4+CD25+ T cells in mice. as unrelated or even mutually exclusive in cancer treatment, Cyclophosphamide (20 mg/kg) decreased the numbers of because chemotherapy kills not only target cancer cells but splenocytes, CD4+ and CD8+ T cells by ~50%, while a decline also immune cells, inducing systemic immune suppression in CD4+CD25+ T cell number was more profound, leading to and dampening the therapeutic efficacy of immunotherapy. the remarkably lower ratios of CD4+CD25+ T cells to CD4+ In this regard, however, cyclophosphamide appears an T cells.
    [Show full text]
  • Intratumoral Immunotherapy for Early Stage Solid Tumors
    Author Manuscript Published OnlineFirst on February 18, 2020; DOI: 10.1158/1078-0432.CCR-19-3642 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 Intratumoral immunotherapy for early-stage solid tumors 2 3 Wan Xing Hong1,2*, Sarah Haebe2,3*, Andrew S. Lee4,5, C. Benedikt Westphalen3,6,7, 4 Jeffrey A. Norton1,2, Wen Jiang8, Ronald Levy2# 5 6 1. Department of Surgery, Stanford University School of Medicine 7 2. Stanford Cancer Institute, Division of Oncology, Department of Medicine, Stanford University 8 3. Department of Medicine III, University Hospital, LMU Munich, Germany 9 4. Department of Pathology, Stanford University School of Medicine 10 5. Shenzhen Bay Labs, Cancer Research Institute, Shenzhen, China 11 6. Comprehensive Cancer Center Munich, Munich, Germany 12 7. Deutsches Konsortium für Translationale Krebsforschung (DKTK), DKTK Partner Site Munich, 13 Germany 14 8. Department of Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas, 15 Texas, USA 16 * These authors contributed equally to this work 17 # Correspondence: [email protected]. 18 CCSR 1105, Stanford, California 94305-5151 19 (650) 725-6452 (office) 20 21 Running title: Intratumoral immunotherapy for early-stage solid tumors 22 23 24 Conflict of Interest 25 Dr. Ronald Levy serves on the advisory boards for Five Prime, Corvus, Quadriga, BeiGene, GigaGen, 26 Teneobio, Sutro, Checkmate, Nurix, Dragonfly, Abpro, Apexigen, Spotlight, 47 Inc, XCella, 27 Immunocore, Walking Fish. 28 Dr. Benedikt Westphalen is on the advisory boards for Celgene, Shire/Baxalta Rafael Pharmaceuticals, 29 Redhill and Roche. He receives research support from Roche.
    [Show full text]
  • Tasmanian Devils' Transmissible Cancer
    Tasmanian devils’ transmissible cancer: Izarbe Aísa Marín Genetics Bachelor’s Degree What is the future? Final Project | June 2017 Introduction Devil Facial Tumor Disease 1Why is Tasmanian devils’ cancer incidence so high? 2Introduction to transmissible cancers Carcinogenesis is thought to occur via Peto’s Paradox represents the lack of accumulation of mutations and mutation correlation between cancer prevalence rates depend on cell number, which and body size or lifespan and it can be Primary Mode of Lack of Capacity for correlates with body size and lifespan. useful to explore cases that are far tumor’s origin transmission allorecognition infinite growth Then, large and long-lived animals from what is expected. Tasmanian should have more cancers than smaller devils suffer from Devil Facial Tumor and shorter-lived ones, due to increased Disease (DFTD), a lethal transmissible The ancestral type of DTDF is thought to be derived from a Schwann cell (clonal number of cell divisions. cancer that is threatening the species origin) and it is transmitted by biting during mating or feeding interactions. to extinction. (2) (1) y = 0,0815 - 0,0061x [y=%Tumors; x=Log(Mass[x]*LifeSpan[y])] 10x DFTD was first reported in Mount William National Park, northeastern Tasmania, in 1996. In 20 years, the disease has spread to more than 85% Forestier of wild Tasmanian devil Peninsula populations, causing severe declines. Immunology of DFTD 3Why devils immune system do not recognize DFTD? (3) Deficiency of devil Marsupials’ immune system is different immune system from, rather than inferior to mammals’ immune system. Immunological Low genetic Slower immune responses tolerance diversity facilitate early transmission events.
    [Show full text]
  • Cancer Immunology, Immunotherapy Editor-In-Chief: H
    Cancer Immunology, Immunotherapy Editor-in-Chief: H. Dong ▶ 94% of authors who answered a survey reported that they would definitely publish or probably publish in the journal again Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology. The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others’ results in different contexts. Cll is especially interested in papers describing clinical trial designs and outcome regardless of whether they met their designated endpoints or not, and particularly those shedding light on immunological mechanisms. CII is affiliated with the Association for Cancer Immunotherapy (CIMT), Canadian Cancer 12 issues/year Immunotherapy Consortium (CCIC), The Japanese Association for Cancer Immunology (JACI), Network Italiano per la Bioterapia dei Tumori (NIBIT),and Sociedad Española de Inmunologia- Electronic access Grupo Española de InmunoTerapia (SEI-GEIT). ▶ link.springer.com CIMT: http://www.cimt.eu/home Subscription information CCIC: http://www.immunotherapycancer.ca/ ▶ springer.com/librarians JACI: http://www.jaci.jp/eng/index.html NIBIT: http://www.nibit.org/index.php SEI-GEIT: http://www.inmunologia.org/grupos/home.php? UpOm5=M&Upfqym5uom=GK CITIM: http://www.canceritim.org Impact Factor: 6.968 (2020), Journal Citation Reports® On the homepage of Cancer Immunology, Immunotherapy at springer.com you can ▶ Sign up for our Table of Contents Alerts ▶ Get to know the complete Editorial Board ▶ Find submission information.
    [Show full text]
  • Prospects for NK Cell Therapy of Sarcoma
    cancers Review Prospects for NK Cell Therapy of Sarcoma Mieszko Lachota 1 , Marianna Vincenti 2 , Magdalena Winiarska 3, Kjetil Boye 4 , Radosław Zago˙zd˙zon 5,* and Karl-Johan Malmberg 2,6,* 1 Department of Clinical Immunology, Doctoral School, Medical University of Warsaw, 02-006 Warsaw, Poland; [email protected] 2 Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, 0310 Oslo, Norway; [email protected] 3 Department of Immunology, Medical University of Warsaw, 02-097 Warsaw, Poland; [email protected] 4 Department of Oncology, Oslo University Hospital, 0310 Oslo, Norway; [email protected] 5 Department of Clinical Immunology, Medical University of Warsaw, 02-006 Warsaw, Poland 6 Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 86 Stockholm, Sweden * Correspondence: [email protected] (R.Z.); [email protected] (K.-J.M.) Received: 15 November 2020; Accepted: 9 December 2020; Published: 11 December 2020 Simple Summary: Sarcomas are a group of aggressive tumors originating from mesenchymal tissues. Patients with advanced disease have poor prognosis due to the ineffectiveness of current treatment protocols. A subset of lymphocytes called natural killer (NK) cells is capable of effective surveillance and clearance of sarcomas, constituting a promising tool for immunotherapeutic treatment. However, sarcomas can cause impairment in NK cell function, associated with enhanced tumor growth and dissemination. In this review, we discuss the molecular mechanisms of sarcoma-mediated suppression of NK cells and their implications for the design of novel NK cell-based immunotherapies against sarcoma.
    [Show full text]
  • AN ANTICANCER DRUG COCKTAIL of Three Kinase Inhibitors Improved Response to a DENDRITIC CELL–BASED CANCER VACCINE
    Author Manuscript Published OnlineFirst on July 2, 2019; DOI: 10.1158/2326-6066.CIR-18-0684 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 AN ANTICANCER DRUG COCKTAIL OF Three Kinase Inhibitors Improved Response to a DENDRITIC CELL–BASED CANCER VACCINE Jitao Guo1, Elena Muse1, Allison J. Christians1, Steven J. Swanson2, and Eduardo Davila1, 3, 4 1Division of Medical Oncology, Department of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, United States; 2Immunocellular Therapeutics Ltd., Westlake Village, California, United States; 3 Human Immunology and Immunotherapy Initiative, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, United States; and 4University of Colorado Comprehensive Cancer Center, Aurora, Colorado, United States. Running Title: REPURPOSING ANTICANCER DRUGS FOR DC CANCER VACCINE Keywords: Dendritic cell; cancer vaccine; MK2206; NU7441; Trametinib Financial supports: This work was supported by R01CA207913, a research award from ImmunoCellular Therapeutics, VA Merit Award BX002142, University of Maryland School of Medicine Marlene and Stewart Greenebaum Comprehensive Cancer Center P30CA134274 and the University of Colorado Denver Comprehensive Cancer Center P30CA046934. Corresponding author: Dr. Eduardo Davila Mail stop 8117,12801 E. 17th Avenue, Aurora, CO 80045 Email: [email protected] Phone: (303) 724-0817; Fax:(303) 724-3889 Conflict of Interest Disclosures: These studies were partly funded by a grant from ImmunoCellular Therapeutics (IMUC). S.S. currently serves as SVP Research IMUC but the remaining authors declare no competing financial interests. Counts: Abstract, 242 words; Manuscript, 4523 words; Figures, 5; References,50. Downloaded from cancerimmunolres.aacrjournals.org on October 2, 2021. © 2019 American Association for Cancer Research.
    [Show full text]
  • 07052020 MR ASCO20 Curtain Raiser
    Media Release New data at the ASCO20 Virtual Scientific Program reflects Roche’s commitment to accelerating progress in cancer care First clinical data from tiragolumab, Roche’s novel anti-TIGIT cancer immunotherapy, in combination with Tecentriq® (atezolizumab) in patients with PD-L1-positive metastatic non- small cell lung cancer (NSCLC) Updated overall survival data for Alecensa® (alectinib), in people living with anaplastic lymphoma kinase (ALK)-positive metastatic NSCLC Key highlights to be shared on Roche’s ASCO virtual newsroom, 29 May 2020, 08:00 CEST Basel, 7 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 19 approved and investigational medicines across 21 cancer types, will be presented at the ASCO20 Virtual Scientific Program organised by the American Society of Clinical Oncology (ASCO), which will be held 29-31 May, 2020. A total of 120 abstracts that include a Roche medicine will be presented at this year's meeting. "At ASCO, we will present new data from many investigational and approved medicines across our broad oncology portfolio," said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development. “These efforts exemplify our long-standing commitment to improving outcomes for people with cancer, even during these unprecedented times. By integrating our medicines and diagnostics together with advanced insights and novel platforms, Roche is uniquely positioned to deliver the healthcare solutions of the future." Together with its partners, Roche is pioneering a comprehensive approach to cancer care, combining new diagnostics and treatments with innovative, integrated data and access solutions for approved medicines that will both personalise and transform the outcomes of people affected by this deadly disease.
    [Show full text]
  • Engineered Marrow Macrophages for Cancer Therapy: Engorgement, Accumulation, Differentiation, and Acquired Immunity
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2017 Engineered Marrow Macrophages For Cancer Therapy: Engorgement, Accumulation, Differentiation, And Acquired Immunity Cory Alvey University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Pharmacology Commons Recommended Citation Alvey, Cory, "Engineered Marrow Macrophages For Cancer Therapy: Engorgement, Accumulation, Differentiation, And Acquired Immunity" (2017). Publicly Accessible Penn Dissertations. 2164. https://repository.upenn.edu/edissertations/2164 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/2164 For more information, please contact [email protected]. Engineered Marrow Macrophages For Cancer Therapy: Engorgement, Accumulation, Differentiation, And Acquired Immunity Abstract The ability of a macrophage to engulf and break down invading cells and other targets provides a first line of immune defense in nearly all tissues. This defining ability ot ‘phagos’ or devour can subsequently activate the entire immune system against foreign and diseased cells, and progress is now being made on a decades-old idea of directing macrophages to phagocytose specific targets such as cancer cells. Physical properties of cancer cells influence phagocytosis and relate via cytoskeleton forces to differentiation pathways in solid tumors. Here, SIRPα on macrophages from mouse and human marrow was inhibited to block recognition of CD47, a ‘marker of self.’ These macrophages were then systemically injected into mice with fluorescent human tumors. Within days, the tumors regressed, and fluorescence analyses showed that the more the SIRPα-inhibited macrophages engulfed, the more they accumulated within tumors. In vitro phagocytosis experiments on transwells revealed that macrophage migration through micropores was inhibited by eating.
    [Show full text]